Biotech Psoriasis Drugs Hit a Cost Ceiling - New York Times
January 23, 2007| Biotech Psoriasis Drugs Hit a Cost Ceiling New York Times, NY - One reason for the slowdown is that Enbrel is losing market share for its main use — as a treatment for rheumatoid arthritis, a different autoimmune disease ... |
Research and Markets: View Results of the Latest ChangeWave ... - Business Wire (press release)
January 23, 2007| Research and Markets: View Results of the Latest ChangeWave ... Business Wire (press release), CA - What is the most promising new treatment on the horizon for the treatment of osteoarthritis? - What is the most common treatment for Rheumatoid Arthritis ... |
Eye on Trubion Pharmaceuticals - Seeking Alpha
January 23, 2007| Eye on Trubion Pharmaceuticals Seeking Alpha, NY - Trubion's programs include TRU-015, being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis [RA], and a Phase I trial for ... |
Safety Monitoring Board Recommends Continuation of EntreMed's MKC ... - Yahoo! News (press release)
January 23, 2007| Safety Monitoring Board Recommends Continuation of EntreMed's MKC ... Yahoo! News (press release) - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
RhuDex(R) Enters Clinical Phase IIa Trial in Rheumatoid Arthritis - Genetic Engineering News (press release)
January 23, 2007| RhuDex(R) Enters Clinical Phase IIa Trial in Rheumatoid Arthritis Genetic Engineering News (press release), NY - RhuDex(R) is a novel, orally available substance for the treatment of rheumatoid arthritis, originating from Active Biotech's patented CD80 antagonists and ... |
4SC Nominates NFkB Development Candidate and Presents New Data at ... - PR Newswire UK (press release)
January 23, 2007| 4SC Nominates NFkB Development Candidate and Presents New Data at ... PR Newswire UK (press release), UK - The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa. Three other product candidates are in pre-clinical ... 4SC Nominates NFkB Development Candidate and Presents New Data at ... |
MediGene Initiates a Clinical Phase - Ad-Hoc-News (Pressemitteilung)
January 23, 2007| MediGene Initiates a Clinical Phase Ad-Hoc-News (Pressemitteilung), Germany - RhuDex® is a novel, orally available T cell co-stimulation modulator for the treatment of rheumatoid arthritis. By specifically blocking T-cell activation ... |